Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)

The durability of a three-dose extended primary series of COVID-19 vaccine in dialysis patients remains unknown. Here, we assessed dynamic changes in SARS-CoV-2-specific humoral and cell-mediated immunity at baseline, 3 months, and 6 months after the extended primary series in 29 hemodialyzed (HD),...

Descrición completa

Detalles Bibliográficos

Principais autores:	Sarinya Boongird, Chavachol Setthaudom, Rungthiwa Kitpermkiat, Somsak Prasongtanakij, Supanart Srisala, Piyatida Chuengsaman, Arkom Nongnuch, Montira Assanatham, Sasisopin Kiertiburanakul, Kumthorn Malathum, Angsana Phuphuakrat, Jackrapong Bruminhent
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2022-07-01
Series:	Vaccines
Assuntos:	COVID-19 vaccine dialysis immune response inactivated SARS-CoV-2 vaccine neutralizing antibody SARS-CoV-2
Acceso en liña:	https://www.mdpi.com/2076-393X/10/7/1064
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!